<SEC-DOCUMENT>0000950170-23-034234.txt : 20230725
<SEC-HEADER>0000950170-23-034234.hdr.sgml : 20230725
<ACCEPTANCE-DATETIME>20230725083228
ACCESSION NUMBER:		0000950170-23-034234
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		16
CONFORMED PERIOD OF REPORT:	20230721
ITEM INFORMATION:		Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
ITEM INFORMATION:		Other Events
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20230725
DATE AS OF CHANGE:		20230725

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			FIBROGEN INC
		CENTRAL INDEX KEY:			0000921299
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-36740
		FILM NUMBER:		231106583

	BUSINESS ADDRESS:	
		STREET 1:		409 ILLINOIS STREET
		CITY:			SAN FRANCISCO
		STATE:			CA
		ZIP:			94158
		BUSINESS PHONE:		415-978-1200

	MAIL ADDRESS:	
		STREET 1:		409 ILLINOIS STREET
		CITY:			SAN FRANCISCO
		STATE:			CA
		ZIP:			94158
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>fgen-20230721.htm
<DESCRIPTION>8-K
<TEXT>
<XBRL>
<?xml version="1.0" encoding="ASCII"?><!-- DFIN New ActiveDisclosure (SM) Inline XBRL Document - http://www.dfinsolutions.com/ --><!-- Creation Date :2023-07-25T08:28:56.2676+00:00 --><!-- Copyright (c) 2023 Donnelly Financial Solutions, Inc. All Rights Reserved. -->
<html xmlns="http://www.w3.org/1999/xhtml" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:nonNumeric="http://www.xbrl.org/dtr/type/non-numeric" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:dei="http://xbrl.sec.gov/dei/2023" xmlns:fgen="http://www.fibrogen.com/20230721" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2022-02-16">
 <head>
  <title>8-K</title>
  <meta http-equiv="Content-Type" content="text/html" />
 </head>
 <body style="margin: auto!important;padding: 8px;">
  <div style="display:none;"><ix:header><ix:hidden><ix:nonNumeric id="F_28525c66-114b-4455-8cdf-d39c53a4ae78" name="dei:EntityCentralIndexKey" contextRef="C_e77ac38f-730b-418a-9522-10e9d9662f00">0000921299</ix:nonNumeric><ix:nonNumeric id="F_1c583dd6-6009-405c-ab35-0f3b37fcbbeb" name="dei:AmendmentFlag" contextRef="C_e77ac38f-730b-418a-9522-10e9d9662f00">false</ix:nonNumeric></ix:hidden><ix:references><link:schemaRef xlink:type="simple" xlink:href="fgen-20230721.xsd"></link:schemaRef></ix:references><ix:resources><xbrli:context id="C_e77ac38f-730b-418a-9522-10e9d9662f00"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000921299</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-21</xbrli:startDate><xbrli:endDate>2023-07-21</xbrli:endDate></xbrli:period></xbrli:context></ix:resources></ix:header></div>
  <p style="border-top:2.25pt double rgba(0,0,0,1);text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:5.75pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:18.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">UNITED STATES<br />SECURITIES AND EXCHANGE COMMISSION<br /></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">WASHINGTON, D.C. 20549</span></p>
  <p style="margin-left:40.0%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;border-bottom:0.75pt solid rgba(0,0,0,1);margin-right:40.0%;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:18.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">FORM </span><span style="font-size:18.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_abfea4ff-d22c-4a80-a9cf-1a47aff7dc79" contextRef="C_e77ac38f-730b-418a-9522-10e9d9662f00" name="dei:DocumentType"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:18.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">8-K</span></ix:nonNumeric></span></p>
  <p style="margin-left:40.0%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;border-bottom:0.75pt solid rgba(0,0,0,1);margin-right:40.0%;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:9.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">CURRENT REPORT</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:9.0pt;font-family:Times New Roman;margin-bottom:6.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934</span></p>
  <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:100.0%;"></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:0.02986111111111111in;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Date of Report (Date of earliest event reported): </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_f77a6d00-8aba-476d-b247-8e45d90b5eed" contextRef="C_e77ac38f-730b-418a-9522-10e9d9662f00" name="dei:DocumentPeriodEndDate" format="ixt:date-monthname-day-year-en"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">July 21, 2023</span></ix:nonNumeric></span></p></td>
   </tr>
  </table>
  <p style="margin-left:40.0%;text-indent:0.0%;font-size:10.0pt;margin-top:5.0pt;font-family:Times New Roman;margin-bottom:0.0pt;border-bottom:0.75pt solid rgba(0,0,0,1);margin-right:40.0%;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:5.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:24.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_babd7872-b8c5-42e3-ba49-27c54ea88821" contextRef="C_e77ac38f-730b-418a-9522-10e9d9662f00" name="dei:EntityRegistrantName"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:24.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">FIBROGEN, INC.</span></ix:nonNumeric></span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:3.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(Exact name of Registrant as Specified in Its Charter)</span></p>
  <p style="margin-left:40.0%;text-indent:0.0%;font-size:10.0pt;margin-top:9.0pt;font-family:Times New Roman;margin-bottom:0.0pt;border-bottom:0.75pt solid rgba(0,0,0,1);margin-right:40.0%;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:20.0%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:20.0%;"></td>
    <td style="width:18.0%;"></td>
    <td style="width:41.0%;"></td>
   </tr>
   <tr style="height:10.0pt;">
    <td colspan="3" style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_9bdf4ac8-6726-40de-8fd0-46c78d1f9f09" contextRef="C_e77ac38f-730b-418a-9522-10e9d9662f00" name="dei:EntityIncorporationStateCountryCode" format="ixt-sec:stateprovnameen"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Delaware</span></ix:nonNumeric></span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_06523b41-fb4e-4388-a66c-61a8b0656083" contextRef="C_e77ac38f-730b-418a-9522-10e9d9662f00" name="dei:EntityFileNumber"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">001-36740</span></ix:nonNumeric></span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_72499b12-0b3c-4635-b3d6-db8c85b75a99" contextRef="C_e77ac38f-730b-418a-9522-10e9d9662f00" name="dei:EntityTaxIdentificationNumber"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">77-0357827</span></ix:nonNumeric></span></p></td>
   </tr>
   <tr style="height:7.0pt;">
    <td colspan="3" style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(State or Other Jurisdiction<br />of Incorporation)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(Commission File Number)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(IRS Employer<br />Identification No.)</span></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td colspan="3" style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_dc16f38a-e4ed-4b94-9f58-96be233595c0" contextRef="C_e77ac38f-730b-418a-9522-10e9d9662f00" name="dei:EntityAddressAddressLine1"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">409 Illinois Street</span></ix:nonNumeric></span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td colspan="3" style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_818421e8-4e43-49ac-b38f-40bc25e274b7" contextRef="C_e77ac38f-730b-418a-9522-10e9d9662f00" name="dei:EntityAddressCityOrTown"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">San Francisco</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_0c4cd83b-260a-48af-a3ac-e2425b9518fb" contextRef="C_e77ac38f-730b-418a-9522-10e9d9662f00" name="dei:EntityAddressStateOrProvince" format="ixt-sec:stateprovnameen"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">California</span></ix:nonNumeric></span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_96beb298-3e34-4b58-8691-b36eebae1e13" contextRef="C_e77ac38f-730b-418a-9522-10e9d9662f00" name="dei:EntityAddressPostalZipCode"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">94158</span></ix:nonNumeric></span></p></td>
   </tr>
   <tr style="height:7.0pt;">
    <td colspan="3" style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(Address of Principal Executive Offices)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(Zip Code)</span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:100.0%;"></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.125in;word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:0.02986111111111111in;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Registrant&#x2019;s Telephone Number, Including Area Code:</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_2db9c82d-1140-43d7-b9c2-9e9a56b24fa0" contextRef="C_e77ac38f-730b-418a-9522-10e9d9662f00" name="dei:CityAreaCode"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">415</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_93c532ed-98e4-4a54-9cf6-bf9f6d41406f" contextRef="C_e77ac38f-730b-418a-9522-10e9d9662f00" name="dei:LocalPhoneNumber"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">978-1200 </span></ix:nonNumeric></span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"></span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:100.0%;"></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.125in;word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_16532756-416c-4bb5-995e-205b60270b17" contextRef="C_e77ac38f-730b-418a-9522-10e9d9662f00" name="dei:EntityInformationFormerLegalOrRegisteredName"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span></ix:nonNumeric>&#160;</span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(Former Name or Former Address, if Changed Since Last Report)</span></p>
  <p style="margin-left:40.0%;text-indent:0.0%;font-size:10.0pt;margin-top:9.35pt;font-family:Times New Roman;margin-bottom:0.0pt;border-bottom:0.75pt solid rgba(0,0,0,1);margin-right:40.0%;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:9.35pt;font-family:Times New Roman;margin-bottom:6.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <div style="text-indent:-24.5pt;padding-left:24.5pt;margin-top:9.0pt;margin-bottom:0.0pt;text-align:left;"><span style="margin-right:1em;margin-right:1em;"><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_b7a198e0-6ddf-4758-af37-f9cd9d5bdb59" contextRef="C_e77ac38f-730b-418a-9522-10e9d9662f00" name="dei:WrittenCommunications" format="ixt-sec:boolballotbox"><span style="font-size:10.0pt;font-family:Times New Roman;">&#9744;</span></ix:nonNumeric></span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</span></div>
  <div style="text-indent:-24.5pt;padding-left:24.5pt;margin-top:6.0pt;margin-bottom:0.0pt;text-align:left;"><span style="margin-right:1em;margin-right:1em;"><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_79df25e5-55d0-48a5-9152-59cef5055e4c" contextRef="C_e77ac38f-730b-418a-9522-10e9d9662f00" name="dei:SolicitingMaterial" format="ixt-sec:boolballotbox"><span style="font-size:10.0pt;font-family:Times New Roman;">&#9744;</span></ix:nonNumeric></span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</span></div>
  <div style="text-indent:-24.5pt;padding-left:24.5pt;margin-top:6.0pt;margin-bottom:0.0pt;text-align:left;"><span style="margin-right:1em;margin-right:1em;"><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_f0a16506-03f6-471a-ab6f-7ea6b6215221" contextRef="C_e77ac38f-730b-418a-9522-10e9d9662f00" name="dei:PreCommencementTenderOffer" format="ixt-sec:boolballotbox"><span style="font-size:10.0pt;font-family:Times New Roman;">&#9744;</span></ix:nonNumeric></span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</span></div>
  <div style="text-indent:-24.5pt;padding-left:24.5pt;margin-top:6.0pt;margin-bottom:0.0pt;text-align:left;"><span style="margin-right:1em;margin-right:1em;"><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_bae60d11-362a-4cfd-9abe-29971de18455" contextRef="C_e77ac38f-730b-418a-9522-10e9d9662f00" name="dei:PreCommencementIssuerTenderOffer" format="ixt-sec:boolballotbox"><span style="font-size:10.0pt;font-family:Times New Roman;">&#9744;</span></ix:nonNumeric></span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</span></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:9.0pt;font-family:Times New Roman;margin-bottom:9.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Securities registered pursuant to Section 12(b) of the Act:</span></p>
  <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:38.0%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:15.0%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:45.0%;"></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.25pt solid;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><br />Title of each class</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.25pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.25pt solid;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Trading<br />Symbol(s)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.25pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.25pt solid;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><br />Name of each exchange on which registered</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_77947213-815a-414f-9ed9-948b4503bb96" contextRef="C_e77ac38f-730b-418a-9522-10e9d9662f00" name="dei:Security12bTitle"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Common Stock, $0.01 par value</span></ix:nonNumeric></span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_bc1453c0-2c15-4b23-89f1-52c000d8dee8" contextRef="C_e77ac38f-730b-418a-9522-10e9d9662f00" name="dei:TradingSymbol"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">FGEN</span></ix:nonNumeric></span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_1fe65379-76d4-4f29-99ab-d1e4d714e185" contextRef="C_e77ac38f-730b-418a-9522-10e9d9662f00" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Nasdaq Global Select Market</span></ix:nonNumeric></span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (&#167;&#x202f;230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (&#167;&#x202f;240.12b-2 of this chapter).</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:9.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Emerging growth company </span><span style="font-size:10.0pt;"><ix:nonNumeric id="F_0e7803b9-98e5-4186-ab5f-6543f1592e16" contextRef="C_e77ac38f-730b-418a-9522-10e9d9662f00" name="dei:EntityEmergingGrowthCompany" format="ixt-sec:boolballotbox"><span style="font-size:10.0pt;font-family:Times New Roman;">&#9744;</span></ix:nonNumeric></span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:9.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. </span><span style="font-size:10.0pt;font-family:Times New Roman;">&#9744;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;border-bottom:2.25pt double rgba(0,0,0,1);text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:6.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Appointment of Interim Chief Executive Officer</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">     On July 25, 2023, FibroGen, Inc. (the &#x201c;Company&#x201d;), announced that the Board of Directors (the &#34;Board&#34;) has appointed Thane Wettig, age 58, to the position of Interim Chief Executive Officer (&#x201c;Interim CEO&#x201d;), effective July 23, 2023. He succeeds Enrique Conterno, who has resigned as Chief Executive Officer and from the Board, and who will remain with the Company as Special Advisor to the Interim CEO through August 8, 2023.   Mr. Conterno&#x2019;s resignation on July 21, 2023 was not the result of any disagreement with the Company. The Company would like to thank Mr. Conterno for his service as Chief Executive Officer and on the Board.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">     Mr. Wettig, who has served as the Company&#x2019;s Chief Commercial Officer since June 2020, has more than 30 years of global biopharmaceutical leadership and commercial experience. Mr. Wettig previously served as Chief Commercial Officer and Metabolic Franchise Head at Intarcia Therapeutics. Prior to joining Intarcia in 2018, Mr. Wettig served as Chief Marketing Officer (Vice President of Global Marketing, Strategy and Alliance Management) for Lilly Diabetes, leading the development and launch of multiple blockbuster diabetes medicines during a period of unprecedented growth of Lilly&#x2019;s diabetes business. Mr. Wettig began his career at Lilly in 1990. He was promoted to Vice President of Global Marketing for Diabetes Brands in 2004, and assumed the role as Chief Marketing Officer for Lilly Diabetes when it was formed in 2009. Mr. Wettig also played an integral role in the design and management of Lilly&#x2019;s highly successful diabetes alliance between Lilly and Boehringer-Ingelheim. He is recognized throughout the industry as a seasoned executive with extensive brand building and launch experience. Mr. Wettig received his M.B.A. and B.A. in biology from Washington University in St. Louis.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Thane Wettig Offer Letter</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">     The Company has entered into an employment offer letter, dated July 23, 2023 (the &#x201c;Offer Letter&#x201d;), with Mr. Wettig. The Offer Letter has no specified term and Mr. Wettig&#x2019;s employment with the Company will be on an at-will basis. The material terms of the Agreement are summarized below.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">     Base Salary and Bonus</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">. Mr. Wettig will receive an additional monthly salary enhancement of $10,000 on top of his annualized base salary of $545,000.  He will remain eligible for an annual bonus under the Company&#x2019;s Non-Equity Incentive Plan with a target amount of 50% of his base salary for the period he has served as Chief Commercial Officer and a target amount of 75% of his base salary (as enhanced) for the period he serves as Interim CEO. His base salary, additional salary stipend and bonus are subject to annual review.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">     Severance Terms</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">. While serving as Interim CEO, in the event Mr. Wettig&#x2019;s employment with the Company terminates for any reason, he will be entitled to certain unpaid and accrued payments and benefits. However, if Mr. Wettig&#x2019;s employment is terminated by the Company for &#x201c;cause,&#x201d; he will be entitled only to limited payments and benefits consisting primarily of earned but unpaid salary and earned but unused paid time off.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">     Change-in-Control Severance Terms. </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> As part of his service as Chief Commercial Officer, the Company entered into its form of change-in-control severance agreement with Mr. Wettig, dated as of June 22, 2023 (the &#x201c;CIC Severance Agreement&#x201d;). This CIC Severance Agreement was amended for the term of his service as Interim CEO by the Offer Letter. Under the terms of the Offer Letter, if Mr. Wettig&#x2019;s employment is terminated by the Company  without &#x201c;cause&#x201d; and other than due to death or disability, or he resigns for &#x201c;good reason,&#x201d; in either case, in connection with or within 12 months following the effective date of a change in control of the Company (&#x201c;CIC Termination&#x201d;), or if Mr. Wettig&#x2019;s employment is terminated by the Company without &#x201c;cause&#x201d; and other than due to death or disability outside the foregoing circumstances (&#x201c;Ordinary Course Termination&#x201d;), he will be entitled to receive the severance payments and benefits set forth below, subject to his timely execution (and non-revocation) of a release of claims in our favor within 60 days following the date of such termination of employment.  Mr. Wettig&#x2019;s relinquishment of the Interim CEO role and resumption of duties as Chief Commercial Officer will not be deemed either a termination by the Company without &#x201c;cause&#x201d; or a voluntary resignation by him for &#x201c;good reason.&#x201d;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">CIC Termination</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#149;     a cash severance payment equal to 24 months of his base salary then in effect;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#149;     a cash severance payment equal to 1.5 times his current target bonus;</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#149;     subject to his timely election of continuation coverage under the Consolidated Omnibus Budget Reconciliation Act of 1985, as</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">     </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">      amended, or another state law equivalent (&#x201c;COBRA&#x201d;), payment by us of COBRA premiums for him and his eligible dependents</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">    </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">      for a period of up to 18 months following the date of his termination of employment; and</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#149;    all outstanding equity awards, including all outstanding stock options, restricted stock unit awards, and performance restricted</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">     stock unit awards held by him will become fully vested and exercisable as of a date immediately prior to the date of his</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">     termination of employment.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Ordinary Course Termination</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#149;    a cash severance payment equal to 18 months of his base salary then in effect; and</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#149;    subject to his timely election of continuation coverage under COBRA, payment by us of COBRA premiums for him and his</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">     eligible dependents for a period of up to 18 months following the date of his termination of employment.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">     Except as described above, the terms and conditions applicable to his existing CIC Severance Agreement will remain in full force and effect.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">  </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">     Notwithstanding the foregoing, to the extent that Mr. Wettig would be entitled to a greater level of severance payments and benefits under the terms and conditions of a severance plan or policy provided by us or our successor to the Company&#x2019;s  other employees being terminated in connection with or within 12 months following a change in control of the Company but for the existence of the change in control severance agreement, he will be entitled to receive the greater of the severance payments and benefits provided under such plan or policy or the change in control severance agreement.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">     The foregoing descriptions of the Offer Letter and the Company&#x2019;s form of CIC Severance Agreement are qualified in their entirety by reference to the full text of the Offer Letter, which is filed as Exhibit 10.1, to this Current Report on Form 8-K and is incorporated by reference herein, and the Company&#x2019;s form of CIC Severance Agreement which was filed as Exhibit 10.4 to the Company&#x2019;s Quarterly Report on Form 10-Q for the quarter ended March 31, 2023, filed with the Securities and Exchange Commission (the &#x201c;SEC&#x201d;) on May 8, 2023, and is incorporated by reference herein. The Company also previously entered into its standard form indemnification agreement with Mr. Wettig, which was filed as Exhibit 10.27 to the Company&#x2019;s Registration Statement on Form S-1 (File No. 333-199069) filed with the SEC on October 23, 2014, and is incorporated by reference herein.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">     There are no arrangements or understandings between Mr. Wettig and any other persons pursuant to which he was selected as Interim CEO. There are also no family relationships between Mr. Wettig and any director or executive officer of the Company and he has no direct or indirect material interest in any transaction required to be disclosed pursuant to Item 404(a) of Regulation S-K.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Enrique Conterno Consulting Agreement</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">     In connection with the resignation of Mr. Conterno, the Company entered into a Consulting with Mr. Conterno, dated July 23, 2023 (the &#x201c;Consulting Agreement&#x201d;), and effective August 9, 2023, to provide services relating to the Company&#x2019;s business at the direction of Mr. Wettig and the Company&#x2019;s Board Chair, Mr. Schoeneck.  In accordance with the Consulting Agreement, Mr. Conterno will receive $35,000 per month, prorated for partial months, and his stock awards will continue to vest in accordance with the existing terms applicable to such awards.   The Consulting Agreement will continue until September 30, 2023, and may be extended by mutual agreement. The preceding summary of the Consulting Agreement does not purport to be complete and is qualified in its entirety by reference to the full text of the Consulting Agreement which is filed as Exhibit 10.2 to this Current Report on Form S-K and incorporated by reference herein.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:6.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Item 8.01 Other Information.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">     On July 25, 2023, the Company issued a press release announcing the appointment of Thane Wettig as the Interim CEO and the resignation of Mr. Conterno as CEO and as a member of the Board, as described above. A copy of this press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:6.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Item 9.01 Financial Statements and Exhibits.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">           (d)    Exhibits</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:12.198%;"></td>
    <td style="width:1.04%;"></td>
    <td style="width:86.763%;"></td>
   </tr>
   <tr>
    <td colspan="3" style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.02in;word-break:break-word;white-space:pre-wrap;padding-left:0.02in;vertical-align:top;padding-bottom:0.02in;border-bottom:0.75pt solid rgba(0,0,0,1);padding-right:0.02in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Exhibit No.</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.02in;word-break:break-word;white-space:pre-wrap;padding-left:0.02in;vertical-align:top;padding-bottom:0.02in;border-bottom:0.75pt solid rgba(255,255,255,0.01);padding-right:0.02in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">  </span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.02in;word-break:break-word;white-space:pre-wrap;padding-left:0.02in;vertical-align:top;padding-bottom:0.02in;border-bottom:0.75pt solid rgba(0,0,0,1);padding-right:0.02in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Description</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.02in;word-break:break-word;white-space:pre-wrap;padding-left:0.02in;vertical-align:top;padding-bottom:0.02in;padding-right:0.02in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.02in;word-break:break-word;white-space:pre-wrap;padding-left:0.02in;vertical-align:top;padding-bottom:0.02in;padding-right:0.02in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.02in;word-break:break-word;white-space:pre-wrap;padding-left:0.02in;vertical-align:top;padding-bottom:0.02in;padding-right:0.02in;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.02in;word-break:break-word;white-space:pre-wrap;padding-left:0.02in;vertical-align:top;padding-bottom:0.02in;padding-right:0.02in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10.1</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.02in;word-break:break-word;white-space:pre-wrap;padding-left:0.02in;vertical-align:top;padding-bottom:0.02in;padding-right:0.02in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">  </span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.02in;word-break:break-word;white-space:pre-wrap;padding-left:0.02in;vertical-align:top;padding-bottom:0.02in;padding-right:0.02in;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><a href="fgen-ex10_1.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Offer Letter, dated July 23, 2023, between FibroGen, Inc. and Thane Wettig.</span><span style="color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></a></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.02in;word-break:break-word;white-space:pre-wrap;padding-left:0.02in;vertical-align:top;padding-bottom:0.02in;padding-right:0.02in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.02in;word-break:break-word;white-space:pre-wrap;padding-left:0.02in;vertical-align:top;padding-bottom:0.02in;padding-right:0.02in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.02in;word-break:break-word;white-space:pre-wrap;padding-left:0.02in;vertical-align:top;padding-bottom:0.02in;padding-right:0.02in;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.02in;word-break:break-word;white-space:pre-wrap;padding-left:0.02in;vertical-align:top;padding-bottom:0.02in;padding-right:0.02in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10.2</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.02in;word-break:break-word;white-space:pre-wrap;padding-left:0.02in;vertical-align:top;padding-bottom:0.02in;padding-right:0.02in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.02in;word-break:break-word;white-space:pre-wrap;padding-left:0.02in;vertical-align:top;padding-bottom:0.02in;padding-right:0.02in;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><a href="fgen-ex10_2.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Consulting Agreement, dated July 23, 2023, between FibroGen, Inc. and Enrique Conterno.</span></a></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.02in;word-break:break-word;white-space:pre-wrap;padding-left:0.02in;vertical-align:top;padding-bottom:0.02in;padding-right:0.02in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.02in;word-break:break-word;white-space:pre-wrap;padding-left:0.02in;vertical-align:top;padding-bottom:0.02in;padding-right:0.02in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.02in;word-break:break-word;white-space:pre-wrap;padding-left:0.02in;vertical-align:top;padding-bottom:0.02in;padding-right:0.02in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.02in;word-break:break-word;white-space:pre-wrap;padding-left:0.02in;vertical-align:top;padding-bottom:0.02in;padding-right:0.02in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">99.1</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.02in;word-break:break-word;white-space:pre-wrap;padding-left:0.02in;vertical-align:top;padding-bottom:0.02in;padding-right:0.02in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.02in;word-break:break-word;white-space:pre-wrap;padding-left:0.02in;vertical-align:top;padding-bottom:0.02in;padding-right:0.02in;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><a href="fgen-ex99_1.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Press release dated July 25, 2023.</span><span style="color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></a></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.02in;word-break:break-word;white-space:pre-wrap;padding-left:0.02in;vertical-align:top;padding-bottom:0.02in;padding-right:0.02in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.02in;word-break:break-word;white-space:pre-wrap;padding-left:0.02in;vertical-align:top;padding-bottom:0.02in;padding-right:0.02in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.02in;word-break:break-word;white-space:pre-wrap;padding-left:0.02in;vertical-align:top;padding-bottom:0.02in;padding-right:0.02in;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.02in;word-break:break-word;white-space:pre-wrap;padding-left:0.02in;vertical-align:top;padding-bottom:0.02in;padding-right:0.02in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">104</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.02in;word-break:break-word;white-space:pre-wrap;padding-left:0.02in;vertical-align:top;padding-bottom:0.02in;padding-right:0.02in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.02in;word-break:break-word;white-space:pre-wrap;padding-left:0.02in;vertical-align:top;padding-bottom:0.02in;padding-right:0.02in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Cover Page Interactive Data File (embedded within the Inline XBRL document).</span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:9.35pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">SIGNATURES</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:9.35pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</span></p>
  <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:6.0%;"></td>
    <td style="width:44.0%;"></td>
    <td style="width:4.0%;"></td>
    <td style="width:46.0%;"></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:4.3pt;font-family:Times New Roman;margin-bottom:4.3pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">FIBROGEN, INC.</span></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:4.3pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Date:</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:4.3pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">July 25, 2023</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:4.3pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">By:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.25pt solid;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:4.3pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">/s/ Michael Lowenstein</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.7pt;font-family:Times New Roman;margin-bottom:9.35pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Michael Lowenstein<br />Chief Legal Officer</span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <hr style="page-break-after:always;" />
 </body>
</html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.1
<SEQUENCE>2
<FILENAME>fgen-ex10_1.htm
<DESCRIPTION>EX-10.1
<TEXT>
<html>
 <head>
  <title>EX-10.1</title>
 </head>
 <body style="margin: auto!important;padding: 8px;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Exhibit 10.1</font></p>
  <p style="text-indent:-4.254%;padding-left:4.08%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">July 23, 2023</font></p>
  <p style="text-indent:-4.254%;padding-left:4.08%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:-4.254%;padding-left:4.08%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:-4.254%;padding-left:4.08%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:-4.254%;padding-left:4.08%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Thane Wettig</font></p>
  <p style="text-indent:-4.254%;padding-left:4.08%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">915 Oak Terrace Road</font></p>
  <p style="text-indent:-4.254%;padding-left:4.08%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Westfield, IN 46074</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:65.556%;text-align:left;"><font style="white-space:pre-wrap;font-size:9.5pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:-4.254%;padding-left:4.08%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Dear Thane,</font></p>
  <p style="text-indent:-4.254%;padding-left:4.08%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.9pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:0.648%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">FibroGen, Inc. (&#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">FibroGen</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#x201d; or the &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Company</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#x201d;) is pleased to offer you the position of Interim Chief Executive Officer (&#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Interim CEO</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#x201d;), reporting to the Board of Directors (the &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Board</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#x201d;), effective July 23, 2023  (the &#34;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Effective Date</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#34;).  The terms of your employment will remain as currently in effect, with the exception of the changes set forth below.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.55pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</font></p>
  <div style="text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(40,40,40,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-family:Times New Roman;justify-content:flex-start;min-width:3.333%;">1.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Compensation</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">. FibroGen will continue to pay you an annual salary of </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">$545,000.00</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">, payable in bi-monthly installments on our regular paydays in accordance with FibroGen's standard payroll policies. In addition, you will receive a $5,000 stipend per pay period, less applicable withholdings, in recognition of your additional responsibilities as Interim CEO. Your stipend will begin as of the Effective Date.  The position is classified as exempt and therefore not eligible for overtime pay. The first and last payment by FibroGen to you will be adjusted, if necessary, to reflect a commencement or termination date other than the first or last working day of a pay period. During your employment at FibroGen you may not be employed by, or consult with, any other company without the express written authorization of the Chairman of the Board of FibroGen.</font></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</font></p>
  <div style="text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(40,40,40,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-family:Times New Roman;justify-content:flex-start;min-width:3.333%;">2.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Equity Awards</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">.  You will continue to be eligible for equity incentive grants,  as authorized by the FibroGen Compensation Committee from time to time and pursuant to the terms and conditions of the FibroGen Equity Plan effective on the date of acceptance of this letter (the &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Equity Plan</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#x201d;), as may be amended or modified from time to time.   Your existing equity awards will continue to vest on the terms and conditions applicable to such awards. </font></div></div>
  <p style="margin-left:3.333%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:3.333%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</font></p>
  <div style="text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(40,40,40,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-family:Times New Roman;justify-content:flex-start;min-width:3.333%;">3.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Bonus Plan</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">. You will continue to be eligible to participate in FibroGen&#x2019;s Incentive Compensation Plan (the &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Bonus Plan</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#x201d;), adopted by FibroGen for its employees on such terms as the Board may determine in its discretion. </font></div></div>
  <p style="margin-left:3.333%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.5pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:3.333%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Under the terms of the Bonus Plan, both corporate and individual performance is assessed annually and subject to final approval by the Board. The target amount, prorated for the periods you have served (or will serve) as Chief Commercial Officer and Interim CEO, shall be 50% and 75%, respectively based on your aggregate annualized pay for each such period, respectively (i.e. including the stipend for the period of your service as Interim CEO). To remain eligible, employees must maintain satisfactory performance and be in an active status on the day of payment.  Payments are expected to occur no later than 15th of March in the year following the performance cycle.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</font></p>
  <div style="text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(40,40,40,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-family:Times New Roman;justify-content:flex-start;min-width:3.333%;">4.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Severance</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">. As you know, you are a party to a Change in Control and Severance Agreement dated June 22, 2023 (the &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">CIC Agreement</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#x201d;) that provides for defined severance benefits upon certain events, subject to terms and conditions set forth in the CIC Agreement.  During the period of time that you are serving as Interim CEO, the following amendments to your CIC Agreement will be in effect:</font></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Arial;justify-content:flex-start;min-width:3.447919145106397%;">a)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">References to &#x201c;base salary&#x201d; shall refer to aggregate salary including the stipend for service as </font></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <div style="margin-left:3.333%;text-indent:0;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;visibility:hidden;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Arial;justify-content:flex-start;min-width:3.447919145106397%;"></font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Interim CEO.</font></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Arial;justify-content:flex-start;min-width:3.447919145106397%;">b)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Section 3(a)(i) &#x2013; All references to eighteen (18) shall be changed to twenty-four (24) and the reference to one (1) shall be changed to one-and-a-half (1.5).</font></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Arial;justify-content:flex-start;min-width:3.447919145106397%;">c)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Section 3(b)(i) &#x2013; All references to twelve (12) shall be changed to eighteen (18).</font></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Arial;justify-content:flex-start;min-width:3.447919145106397%;">d)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Section 3(b)(i) &#x2013; The reference to twelve (12) shall be changed to eighteen (18).</font></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:3.333%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">When you cease serving as Interim CEO, these terms will cease, and you will again be subject to the terms of the CIC Agreement that were in effect as of the effective date of the CIC Agreement.  You further acknowledge and agree that the end of your service as Interim CEO and return to serving as a bona fide Executive Vice President, Chief Commercial Officer will not constitute &#x201c;Good Reason&#x201d; as defined in the CIC Agreement and will not be treated as termination by the Company without &#x201c;Cause&#x201d; (as defined in the CIC Agreement).</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">In the event of conflict between the terms contained in this offer letter and any other document, the terms of this offer letter (including any amendment to this letter) shall control.  FibroGen reserves the right to amend the terms contained in this offer letter from time to time.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">  </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Thank you for your continued service to FibroGen.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Sincerely,</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">_______________________________</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Jim Schoeneck</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Chairman of the Board</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:-20.0%;padding-left:16.667%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">ACCEPTED AND AGREED TO this</font></p>
  <p style="text-indent:-20.0%;padding-left:16.667%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:-20.0%;padding-left:16.667%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:-20.0%;padding-left:16.667%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">_______Day of _______________, 2023</font></p>
  <table style="border-spacing:0;table-layout:fixed;width:39.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:100.0%;"></td>
   </tr>
   <tr style="height:30.95pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.075in;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.075in;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.075in;vertical-align:top;padding-right:0.075in;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Name</font></p></td>
   </tr>
   <tr style="height:24.5pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.075in;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.075in;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</font></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.075in;vertical-align:top;padding-right:0.075in;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</font></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <hr style="page-break-after:always;">
 </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.2
<SEQUENCE>3
<FILENAME>fgen-ex10_2.htm
<DESCRIPTION>EX-10.2
<TEXT>
<html>
 <head>
  <title>EX-10.2</title>
 </head>
 <body style="margin: auto!important;padding: 8px;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Exhibit 10.2</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);font-variant:small-caps;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Consulting Agreement</font></p>
  <p style="text-indent:-6.188%;padding-left:5.84%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:-6.188%;padding-left:5.84%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">	This Consulting Agreement (&#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Agreement</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x201d;) dated as of July 23, 2023, is effective as of August 9, 2023 (&#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Effective Date</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x201d;), by and between </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">FibroGen, Inc.</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, a Delaware corporation with its principal offices located at 409 Illinois Street, San Francisco, California 94158 and its subsidiaries (collectively &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">FibroGen</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x201d;) and</font><font style="background-color:rgba(0,0,0,0);font-variant:small-caps;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Enrique Conterno</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, an individual residing at 3014 Breakers Drive, Corona del Mar, CA 92625 (&#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Consultant</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x201d;).</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Parties hereby agree as follows:</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <div style="text-indent:6.667%;font-size:0;margin-top:0.0pt;justify-content:flex-start;margin-bottom:0.0pt;min-width:6.667%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.4%;">1.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">CONSULTANCY</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">.  FibroGen hereby retains Consultant and Consultant hereby accepts such retention, commencing on the Effective Date of this Agreement and continuing until September 30, 2023 thereafter at which time this agreement will be completed (&#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Term</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x201d;), unless such Term is extended by the Parties by mutual written consent.  </font></div></div>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <div style="text-indent:6.667%;font-size:0;margin-top:0.0pt;justify-content:flex-start;margin-bottom:0.0pt;min-width:6.667%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.4%;">2.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">SERVICES</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">.  Consultant shall provide consultation services to FibroGen relating to FibroGen business, including support to the Interim CEO and Board Chairperson and such other services as requested by FibroGen (&#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Services</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x201d;).  All Services to be provided by Consultant under this Agreement shall be initiated on behalf of FibroGen by Thane Wettig or Jim Schoeneck (as the coordinators of all requests) or their designated representatives or successor.  The Consultant has no arrangement or relationship with any other party that is competitive with the interests of FibroGen in the subject matter of this Agreement and will not enter into any such arrangement or relationship during the Term of this Agreement.  All deliverables to be delivered by Consultant (&#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Deliverables</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x201d;) under this Agreement shall be delivered in a manner suitable for its intended use.</font></div></div>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <div style="text-indent:6.667%;font-size:0;margin-top:0.0pt;justify-content:flex-start;margin-bottom:0.0pt;min-width:6.667%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.4%;">3.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">EMPLOYMENT OF ASSISTANTS; ASSIGNMENT.  This Agreement is for the personal services of Consultant based on Consultant&#x2019;s unique expertise and assistants may not be utilized, and the Agreement may not be assigned by Consultant, nor shall it be assignable by operation of law without the prior written consent of FibroGen.</font></div></div>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <div style="text-indent:6.667%;font-size:0;margin-top:0.0pt;justify-content:flex-start;margin-bottom:0.0pt;min-width:6.667%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.4%;">4.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">COMPENSATION; EQUITY AWARD VESTING.  FibroGen agrees to pay to Consultant and Consultant agrees to accept for Consultant&#x2019;s Services under this Agreement $35,000.00 USD per month for Services, pro-rated for partial months.</font></div></div>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">FibroGen agrees to pay Consultant within ten (10) days of the end of each month, provided that Consultant has submitted a properly completed, signed and dated IRS Form W-9 to FibroGen.  If travel is required to perform Services, all travel expenses must be pre-approved in writing by FibroGen and in compliance with FibroGen&#x2019;s then-current travel policy, and FibroGen shall reimburse Consultant&#x2019;s reasonable out-of-pocket travel expenses, in accordance with such travel policy. All such invoices relating to this Agreement must be sent to.</font></p>
  <p style="margin-left:13.333%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Accounts Payable (L:         )</font></p>
  <p style="margin-left:13.333%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">FibroGen Inc.</font></p>
  <p style="margin-left:13.333%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">409 Illinois Street</font></p>
  <p style="margin-left:13.333%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">San Francisco, CA 94158</font></p>
  <p style="margin-left:13.333%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">AP@FibroGen.com</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">	Consultant shall continue to vest in Consultant&#x2019;s outstanding equity awards with the Company in accordance with the terms thereof for the term of this Agreement.</font></p>
  <p style="margin-left:13.333%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <div style="text-indent:6.667%;font-size:0;margin-top:0.0pt;justify-content:flex-start;margin-bottom:0.0pt;min-width:6.667%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.4%;">5.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">TIMES AND PLACES OF PROVIDING SERVICES</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">.  Consultant shall generally have the discretion to determine the times and places of rendering Services as well as the method of accomplishing Consultant&#x2019;s Services. FibroGen may reasonably request that Consultant perform some Services at FibroGen&#x2019;s principal office or other locations, which request should be reasonably considered by Consultant.</font></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:16.667%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <div style="margin-left:6.667%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:10.0%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:10.7143239797285%;">6.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">EQUIPMENT, DOCUMENTATION AND SPECIFICATIONS</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">.  </font></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(a)  	Consultant shall supply all equipment and instruments required to perform the Services under this Agreement on location at FibroGen, except when such equipment (including computer, printer, record storage cabinets, telephone, Fax machine, and related information technology equipment) or supplies are unique to FibroGen, in which case FibroGen shall provide Consultant with such equipment, instruments, documentation and specifications as may be reasonably required by Consultant for the performance of Services.  Such equipment, instruments, documentation and specifications shall at all times remain the property of FibroGen. Consultant shall use all such provided equipment and instruments for its intended purpose in a safe manner and in strict compliance with FibroGen&#x2019;s or its vendors&#x2019; instructions and all applicable laws, rules, and regulations.</font></p>
  <p style="text-indent:5.84%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> 	(b)	Upon expiration or termination of this Agreement, Consultant shall promptly deliver to FibroGen all equipment and instruments furnished by FibroGen hereunder, documentation and specifications, as well as all records, manuals, books, blank forms, letters, notes, notebooks, reports, data, schematics, drawings, designs, or copies of the foregoing, and all other trade secrets, property, and confidential information of FibroGen including, but not limited to, all documents that in whole or in part contain any trade secret or Confidential Information (as defined in Section 7) of FibroGen which are in Consultant&#x2019;s possession or under Consultant&#x2019;s control, and further including any of the above stored in electromagnetic media such as ROMs, discs, tapes or cards, and Consultant shall not retain in Consultant&#x2019;s possession or control any such materials or copies or embodiments thereof without the prior express written consent of FibroGen in each instance.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">  </font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <div style="margin-left:5.065%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:12.0pt;min-width:4.935%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:5.198293569284246%;">7.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">NONDISCLOSURE.</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">   </font></div></div>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(a)  	&#x201c;Confidential Information&#x201d; means information disclosed to Consultant or is generated or becomes known to Consultant as a consequence of or through performance of Services for FibroGen, and includes trade secrets and any other proprietary information relating to the business and/or field of interest of FibroGen or of any entity which controls, is controlled by, or under common control with FibroGen including, but not limited to, information relating to inventions, disclosures, processes, systems, methods, formulas, patent applications, machinery, materials, manufacturing techniques, research activities and plans, costs of production, contract forms, prices, volume of sales, promotion methods, business secrets, financial information, lists of names or classes of customers, and information of third parties to whom FibroGen owes a duty of confidentiality. For clarity, Inventions, Data, and Deliverables are deemed part of Confidential Information.  Information shall not be considered Confidential Information to the extent Consultant can demonstrate upon competent written proof that such</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Consulting Agreement</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Ref:</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">		</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">CONFIDENTIAL</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">information (i) is already known to the Consultant at the time of disclosure and such information was not acquired directly or indirectly from FibroGen, (ii) is in the public domain prior to or becomes part of the public domain after disclosure other than through breach of this Agreement by Consultant or unauthorized acts or omissions of Consultant; or (iii) is disclosed in good faith to Consultant by an independent third party lawfully entitled to make such disclosure.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> 	 	(b)	Consultant shall protect and keep all Confidential Information in strict confidence and trust and use the same standard of care used by Consultant to protect her own confidential information, but in any event, shall use at least a reasonable standard of care to protect FibroGen&#x2019;s Confidential Information.  Consultant may use Confidential Information solely for the purpose of providing Services under this Agreement.  Consultant shall not disclose any Confidential Information to any third party without FibroGen&#x2019;s prior written consent.  Except to the extent required in the performance of Services for FibroGen, or as otherwise pre-approved by FibroGen in writing, Consultant will not directly, indirectly or otherwise, use, permit others to use, disseminate, disclose, lecture upon or publish articles containing any Confidential Information. The Consultant hereby agrees that for any violation of this Section 6, FibroGen shall be entitled, in addition to any other remedies it may have, to specific performance, injunctions or other appropriate orders to correct or restrain any such breach by Consultant.  Upon expiration of this Agreement or termination of this Agreement, or otherwise upon the request of FibroGen, Consultant will promptly return all Confidential Information to FibroGen (including copies and embodiments thereof) in Consultant&#x2019;s possession or under Consultant&#x2019;s control or, if so requested by FibroGen, destroy such information (and provide certification of such destruction to FibroGen), except that one (1) secure copy thereof may be retained in her archives solely to demonstrate compliance with the terms of this Agreement.  Consultant will not withhold from FibroGen any Confidential Information as a means of resolving any dispute.  Consultant will not utilize Confidential Information for any purpose except to render the Services.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">  </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font></p>
  <div style="margin-left:6.667%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.571084182443509%;">8.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">OWNERSHIP; INTELLECTUAL PROPERTY.</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">  </font></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">		(a)	&#x201c;Inventions&#x201d; means any and all intellectual property which: (i) are conceived, reduced to practice or made by Consultant for FibroGen under this Agreement, or (ii) result from Services performed by Consultant, individually or in conjunction with others, for FibroGen; or (iii) are made, conceived or reduced to practice with FibroGen&#x2019;s equipment, supplies, facilities or Confidential Information. Inventions shall include, without limitation: (x) discoveries, inventions, concepts and ideas, whether patentable or not, processes, methods, formulas, compositions, techniques, articles and machines, as well as improvements thereof; and (y) trade secrets, trademarks, copyrights and know-how relating to the business and/or field of interest of FibroGen or any entity which controls, is controlled by or under common control with FibroGen. In additional consideration of the fees paid to Consultant, the parties hereby expressly agree that any and all copyrights relating to any and all works of authorship created by Consultant under this Agreement that are protectable under the copyright laws of the United States are and shall be the sole property of FibroGen.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">  </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> 		(b)	All Inventions shall be the sole and exclusive property of FibroGen.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">  </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">		(c)	Except as otherwise expressly provided herein, Consultant hereby agrees to, without royalty or other further consideration to Consultant therefor, but at the reasonable expense of FibroGen:</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Consulting Agreement</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Ref:</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">		</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">CONFIDENTIAL</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">			(i)	As promptly as known or possessed by Consultant, disclose to FibroGen all information with respect to any Invention conceived, reduced to practice or made by Consultant or of which Consultant becomes aware;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">			(ii)	Assign all right, title and interest in and to any such Inventions to FibroGen.  Whenever requested to do so by FibroGen, Consultant shall promptly execute assignments and other related instruments to effect the assignment of all proprietary interests in and to such Inventions to FibroGen as FibroGen shall deem reasonably necessary to apply for and obtain letters patent, trademark and/or copyright registrations of the United States and of foreign countries for said Inventions and to assign and convey to FibroGen or FibroGen&#x2019;s nominee the sole and exclusive right, title and interest in and to the Inventions or any applications, patents and registrations thereon;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font></p>
  <p style="text-indent:20.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(iii) 	Whenever requested to do so by FibroGen, deliver to FibroGen evidence for interference purposes or other legal proceedings.  FibroGen shall reimburse Consultant&#x2019;s reasonable pre-approved out-of-pocket expenses, including travel expenses for such delivery; and</font></p>
  <p style="text-indent:20.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:0.84%;text-indent:19.336%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(iv)	Do such other acts as may be reasonably necessary in FibroGen&#x2019;s sole opinion to obtain and maintain United States and foreign letters patents, trademark and/or copyright registrations for Inventions.  If Consultant should be required to perform such acts after the termination or expiration of this Agreement, FibroGen shall reimburse Consultant&#x2019;s reasonable out-of-pocket expenses, including travel expenses and pay Consultant at a reasonable rate for performing such other acts so long as such performance does not also include Services included in Subsection (b) above.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">		(d) 	All Data and Deliverables under this Agreement are and shall be the sole property of FibroGen.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">  </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(e) 	Consultant hereby (i) acknowledges and agrees that Consultant has no interests in Confidential Information, Data, Deliverables or Inventions, and (ii) covenants that she will not lien or encumber, or otherwise cause, permit or consent to the granting of a lien or encumbrance of the Confidential Information, Data, Deliverables or Inventions.</font></p>
  <p style="margin-left:0.84%;text-indent:19.336%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <div style="text-indent:6.667%;font-size:0;margin-top:0.0pt;justify-content:flex-start;margin-bottom:0.0pt;min-width:6.667%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.4%;">9.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">[RESERVED].</font></div></div>
  <p style="margin-left:10.0%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <div style="text-indent:6.667%;font-size:0;margin-top:0.0pt;justify-content:flex-start;margin-bottom:0.0pt;min-width:6.667%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.4%;">10.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">INDEPENDENT CONTRACTOR STATUS</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">.  It is the express intention of the Parties that Consultant is an independent contractor and not an employee, agent, joint venturer or partner of FibroGen.  Nothing in this Agreement shall be interpreted or construed as creating or establishing the relationship of employer and employee between FibroGen and Consultant. Both Parties acknowledge that Consultant is not an employee for state or federal tax purposes. Consultant shall retain the right to perform Services for others during the Term of this Agreement, provided such service does not constitute a conflict of interest as set forth in Section 1 or violate or threaten the confidentiality and non-use provisions set forth in Section 8 above.  Neither party hereto shall be liable for any act or omission of the other party or for any obligation or debt incurred by the other.</font></div></div>
  <p style="margin-left:6.667%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Consultant shall be obligated to pay any and all applicable social security taxes and federal, state and local income taxes, unemployment insurance and other charges and shall be responsible for making appropriate filings and payments to the applicable taxing authorities, including payments of all withholding and payroll taxes due on compensation received hereunder.  It is Consultant&#x2019;s responsibility to comply with all laws relating to workers&#x2019; compensation insurance, and it is expressly understood that</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">4</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Consulting Agreement</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Ref:</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">		</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">CONFIDENTIAL</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">FibroGen shall not provide workers&#x2019; compensation insurance for Consultant or for any of Consultant&#x2019;s employees or agents.  Consultant shall indemnify, defend and hold FibroGen harmless for any and all claims arising out of injury, disability, or death of Consultant and Consultant&#x2019;s employees or agents resulting from the performance of the Services.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <div style="text-indent:6.667%;font-size:0;margin-top:0.0pt;justify-content:flex-start;margin-bottom:0.0pt;min-width:6.667%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.4%;">11.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">LIMITATION OF LIABILITY.</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">  The entire liability of the parties with respect to the performance by Consultant of the duties hereunder is set forth in this Agreement.  In no event shall either party be liable for any indirect, incidental, special or consequential damages arising out of or in connection with the Services, whether or not FibroGen has been advised or is otherwise on notice of such possibility.  Moreover, in no event shall either party be liable for any claims for personal injury or for property damage arising out of or resulting from Services rendered by Consultant hereunder.  In any event, except to the extent of a party&#x2019;s gross negligence, willful misconduct, each party&#x2019;s liability pursuant to this Section 13 shall be limited to the aggregate amounts paid under this Agreement and further disclaims any liability for incidental, collateral, special or consequential damages, losses or expenses.    </font></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <div style="text-indent:6.667%;font-size:0;margin-top:0.0pt;justify-content:flex-start;margin-bottom:0.0pt;min-width:6.667%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.4%;">12.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">NO EXPORT.</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">  Consultant acknowledges that Confidential Information or other information disclosed in connection with the Services may be considered technical data that is subject to compliance with the export control laws and regulations of the United States, and hereby agrees to comply with such laws.</font></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font></p>
  <div style="text-indent:6.667%;font-size:0;margin-top:0.0pt;justify-content:flex-start;margin-bottom:0.0pt;min-width:6.667%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.4%;">13.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">NOTICE.</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">   Any notice required or permitted to be given hereunder shall be mailed by registered or certified mail, with return receipt requested, overnight courier, or delivered by hand to the party to whom such notice is required or permitted to be given when mailed.  If mailed, any such notice shall be deemed to have been given when mailed, as evidenced by the postmark at the point of mailing.  If delivered by hand, any such notice shall be deemed to have been given when received by the party to whom notice is given, as evidenced by written and dated receipt of the receiving party.</font></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">	Any notice to FibroGen shall be addressed to:</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">	                        FibroGen Inc.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">               	                Legal Department</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">	                       409 Illinois Street</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">  	                       San Francisco, CA 94158</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">	</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">	Any notice to the Consultant shall be addressed to:</font></p>
  <p style="margin-left:6.667%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Enrique Conterno</font></p>
  <p style="margin-left:6.667%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3014 Breakers Drive,</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font></p>
  <p style="margin-left:6.667%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Corona del Mar</font></p>
  <p style="margin-left:6.667%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">CA 92625</font></p>
  <p style="margin-left:20.0%;text-indent:8.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">	Either Party may change the address to which notice to it is to be addressed by notice as provided herein.</font></p>
  <div style="text-indent:7.467%;font-size:0;margin-top:0.0pt;justify-content:flex-start;margin-bottom:0.0pt;min-width:7.463%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:1.604%;">14.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">TERMINATION.</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">  Notwithstanding any other provision of the Agreement, FibroGen may terminate this Agreement upon written notice to Consultant. Consultant may terminate this Agreement upon thirty (30) days written notice to FibroGen.</font></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">5</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Consulting Agreement</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Ref:</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">		</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">CONFIDENTIAL</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <div style="text-indent:6.667%;font-size:0;margin-top:0.0pt;justify-content:flex-start;margin-bottom:0.0pt;min-width:6.667%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.4%;">15.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">SURVIVAL OF CERTAIN AGREEMENTS.</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">   The covenants and agreements set forth in Sections 7-12, 14, and 18-21 shall survive termination of this Agreement and Consultant&#x2019;s Services hereunder and remain in full force and effect regardless of the cause of such termination.</font></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <div style="text-indent:6.667%;font-size:0;margin-top:0.0pt;justify-content:flex-start;margin-bottom:0.0pt;min-width:6.667%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.4%;">16.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">BINDING EFFECT.</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">   This Agreement shall be binding upon and shall inure to the benefit of the Parties hereto and their successors and assigns. </font></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <div style="text-indent:6.667%;font-size:0;margin-top:0.0pt;justify-content:flex-start;margin-bottom:0.0pt;min-width:6.667%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.4%;">17.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">SEVERABILITY.</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">   If any provision of this Agreement shall be held to be invalid, illegal or unenforceable, the validity, legality or enforceability of the remaining provisions shall not be in any way affected or impaired thereby. </font></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <div style="text-indent:6.667%;font-size:0;margin-top:0.0pt;justify-content:flex-start;margin-bottom:0.0pt;min-width:6.667%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.4%;">18.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">GOVERNING LAW.</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> This Agreement shall be governed by the laws of the State of California and the United States of America, without reference to conflict of laws principles. All actions or proceedings relating to this Agreement shall be maintained in a court located in the City and County of San Francisco, California and the Parties hereto consent to the jurisdiction of said court and waive any objection to said venue.</font></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <div style="text-indent:6.667%;font-size:0;margin-top:0.0pt;justify-content:flex-start;margin-bottom:0.0pt;min-width:6.667%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.4%;">19.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">ENTIRE AGREEMENT.</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">  This Agreement contains the entire agreement of the Parties relating to the subject matter hereof, and supersedes all prior and contemporaneous negotiations, correspondence, understandings and agreements of the Parties, except as otherwise provided herein, relating to the subject matter hereof.  It may be amended only by an agreement in writing signed by the Parties.</font></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <div style="text-indent:6.667%;font-size:0;margin-top:0.0pt;justify-content:flex-start;margin-bottom:0.0pt;min-width:6.667%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.4%;">20.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">THIRD PARTY BENEFICIARIES</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">.  The provisions set forth in this Agreement are for the sole benefit of the Parties hereto and their successors and assigns, and shall not be construed as conferring any rights on any other persons.</font></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <div style="text-indent:6.667%;font-size:0;margin-top:0.0pt;justify-content:flex-start;margin-bottom:0.0pt;min-width:6.667%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.4%;">21.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">COUNTERPARTS</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">.  This Agreement may be executed in two or more counterparts, each of which shall be deemed an original, but all of which together shall constitute one and the same instrument.  Counterparts may be signed and delivered by facsimile and/or via portable document format (pdf), each of which shall be binding when sent. </font></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">IN WITNESS WHEREOF, the Parties have executed this Consulting Agreement as of the Effective Date.</font></p>
  <table style="margin-left:1.0%;border-spacing:0;table-layout:fixed;width:93.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:8.562%;"></td>
    <td style="width:36.627%;"></td>
    <td style="width:7.602%;"></td>
    <td style="width:8.662%;"></td>
    <td style="width:38.548%;"></td>
   </tr>
   <tr style="height:20.15pt;">
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.075in;vertical-align:bottom;padding-right:0.075in;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);font-variant:small-caps;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">FibroGen, Inc.</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.075in;vertical-align:bottom;padding-right:0.075in;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.075in;vertical-align:bottom;padding-right:0.075in;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);font-variant:small-caps;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Enrique Conterno</font></p></td>
   </tr>
   <tr style="height:20.15pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.075in;vertical-align:bottom;padding-right:0.075in;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">By:</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.075in;vertical-align:bottom;border-bottom:0.5pt solid;padding-right:0.075in;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.075in;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);padding-right:0.075in;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.075in;vertical-align:bottom;padding-right:0.075in;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">By:</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.075in;vertical-align:bottom;border-bottom:0.5pt solid;padding-right:0.075in;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font></p></td>
   </tr>
   <tr style="height:20.15pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.075in;vertical-align:bottom;padding-right:0.075in;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Name:</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.075in;vertical-align:bottom;border-bottom:0.5pt solid;padding-right:0.075in;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.075in;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);padding-right:0.075in;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.075in;vertical-align:bottom;padding-right:0.075in;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Name:</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.075in;vertical-align:bottom;border-bottom:0.5pt solid;padding-right:0.075in;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font></p></td>
   </tr>
   <tr style="height:20.15pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.075in;vertical-align:bottom;padding-right:0.075in;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Title:</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.075in;vertical-align:bottom;border-bottom:0.5pt solid;padding-right:0.075in;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.075in;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);padding-right:0.075in;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.075in;vertical-align:bottom;padding-right:0.075in;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Title:</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.075in;vertical-align:bottom;border-bottom:0.5pt solid;padding-right:0.075in;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">6</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Consulting Agreement</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Ref:</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">		</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">CONFIDENTIAL</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <hr style="page-break-after:always;">
 </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>4
<FILENAME>fgen-ex99_1.htm
<DESCRIPTION>EX-99.1
<TEXT>
<html>
 <head>
  <title>EX-99.1</title>
 </head>
 <body style="margin: auto!important;padding: 8px;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Exhibit 99.1</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><img src="img3914235_0.jpg" alt="img3914235_0.jpg" style="width:303px;height:79px;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:14.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:14.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:14.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><br></font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:14.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:14.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">FibroGen Announces Leadership Transition</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:14.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="white-space:pre-wrap;font-size:14.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Appoints Thane Wettig as Interim Chief Executive Officer</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> Wettig succeeds Enrique Conterno and brings over 30 years of global pharmaceutical leadership</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">SAN FRANCISCO, July 25, 2023 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN), today announced the appointment of Thane Wettig as the Company&#x2019;s interim Chief Executive Officer effective as of July 23, 2023. Mr. Wettig has served as FibroGen&#x2019;s Chief Commercial Officer and a key member of the senior leadership team since June 2020. Mr. Wettig succeeds Chief Executive Officer Enrique Conterno, who resigned due to personal reasons. To support Mr. Wettig, Mr. Conterno will serve as a Special Advisor to the CEO during a transition period.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">  </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x201c;Thane has been a highly effective leader for the Company over the last three years, and we have full confidence he will deliver as our Interim CEO.  I look forward to working closely with him as we advance the Company&#x2019;s strategic priorities,&#x201d; said Jim Schoeneck, Chairman of the FibroGen Board of Directors.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x201c;I am energized to have the opportunity to lead FibroGen and create value for shareholders and patients through our pamrevlumab phase 3 readouts, advancing our innovative pipeline, and continuing to build on our success with roxadustat in China and the nearly 30 other countries in which it is approved,&#x201d; said Wettig. &#x201c;We have a strong cash position, and have built a great team at FibroGen, including a highly experienced and collaborative leadership team. I am grateful to have the opportunity to continue our work as we apply groundbreaking science with the goal of helping patients around the world.&#x201d;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x201c;I have worked with Thane for many years and am confident that he will lead our world-class management team in continuing to execute on our late stage pamrevlumab programs, expand our rapidly growing roxadustat business in China and other territories, and accelerate development of our early-stage oncology pipeline,&#x201d; said Conterno.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x201c;On behalf of the board, I would like to thank Enrique for his commitment to patients and to FibroGen over the past three and a half years,&#x201d; said Schoeneck. &#x201c;Enrique has been key in building the Company&#x2019;s strong team and culture, enhancing the product pipeline, and driving both late-stage clinical execution and roxadustat commercial success in China.&#x201d;</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Mr. Wettig, who has served as the Company&#x2019;s Chief Commercial Officer since June 2020, has more than 30 years of global biopharmaceutical leadership and commercial experience. Mr. Wettig previously served as Chief Commercial Officer and Metabolic Franchise Head at Intarcia Therapeutics. Prior to joining Intarcia in 2018, Mr. Wettig served as Chief Marketing Officer (Vice President of Global Marketing, Strategy and Alliance Management) for Lilly Diabetes, leading the development and launch of multiple blockbuster diabetes medicines during a period of unprecedented growth of Lilly&#x2019;s diabetes business. Mr. Wettig began his career at Lilly in 1990, and served in multiple leadership roles of increasing responsibility during his Lilly tenure.  He is recognized throughout the industry as a seasoned</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">executive with extensive strategy, brand building and leadership experience. Mr. Wettig received his M.B.A. and B.A. in biology from Washington University in St. Louis.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">About FibroGen</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">  </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">FibroGen, Inc. is a biopharmaceutical company committed to discovering, developing, and commercializing a pipeline of first-in-class therapeutics. The Company applies its pioneering expertise in connective tissue growth factor (CTGF) biology and hypoxia-inducible factor (HIF) to advance innovative medicines for the treatment of unmet needs. Pamrevlumab, an anti-CTGF human monoclonal antibody, is in clinical development for the treatment of locally advanced unresectable pancreatic cancer (LAPC), metastatic pancreatic cancer, and ambulatory Duchenne muscular dystrophy (DMD). Roxadustat (&#x7231;&#x745e;&#x5353;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:7.37pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#174;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, EVRENZO</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:7.37pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">TM</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">) is currently approved in China, Europe, Japan, and numerous other countries for the treatment of anemia in CKD patients on dialysis and not on dialysis. Roxadustat is in clinical development for chemotherapy-induced anemia (CIA) in China. FibroGen recently expanded its research and development portfolio to include product candidates in the immuno-oncology space along with an exclusive license for FOR46. For more information, please visit www.fibrogen.com.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Forward-Looking Statements</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">This release contains forward-looking statements regarding FibroGen&#x2019;s strategy, future plans and prospects, and the development and commercialization of the company&#x2019;s product candidates. These forward-looking statements include, but are not limited to, statements about FibroGen&#x2019;s plans and objectives and typically are identified by use of terms such as &#x201c;may,&#x201d; &#x201c;will&#x201d;, &#x201c;should,&#x201d; &#x201c;on track,&#x201d; &#x201c;could,&#x201d; &#x201c;expect,&#x201d; &#x201c;plan,&#x201d; &#x201c;anticipate,&#x201d; &#x201c;believe,&#x201d; &#x201c;estimate,&#x201d; &#x201c;predict,&#x201d; &#x201c;potential,&#x201d; &#x201c;continue&#x201d; and similar words, although some forward-looking statements are expressed differently. FibroGen&#x2019;s actual results may differ materially from those indicated in these forward-looking statements due to risks and uncertainties related to the continued progress and timing of its various programs, including the enrollment and results from ongoing and potential future clinical trials, and other matters that are described in our Annual Report on Form 10-K for the fiscal year ended December 31, 2022 and our Quarterly Report on Form 10-Q for the quarter ended March 31, 2023, each as filed with the Securities and Exchange Commission (SEC), including the risk factors set forth therein. Investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this release, and FibroGen undertakes no obligation to update any forward-looking statement in this press release, except as required by law.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Contacts: FibroGen, Inc.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Investors:</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Meichiel Keenan</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">mkeenan@fibrogen.com</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Media:</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Michael Szumera</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">mszumera@fibrogen.com</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <hr style="page-break-after:always;">
 </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>5
<FILENAME>img3914235_0.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img3914235_0.jpg
M_]C_X  02D9)1@ ! 0$ W #<  #_VP!#  (! 0$! 0(! 0$" @(" @0# @("
M @4$! ,$!@4&!@8%!@8&!PD(!@<)!P8&" L("0H*"@H*!@@+# L*# D*"@K_
MVP!# 0(" @(" @4# P4*!P8'"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*
M"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@K_P  1" "U K8# 2(  A$! Q$!_\0
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M&DP<?*"">G%<M^R=J/BS6?@-X>\2^,?BC)XQNM5M?MJ:Y)H_V!I8I6+1KY)
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MKRVCC*#G-M6=M/\ A@Q6+J4*BC&Q_5A\"OC5\/\ ]HWX3Z+\:OA3J4UYX?\
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M[S[=X5\06_$EG< ?=/\ ?B<?*Z'AE)JJ<D]'M^1,H]MR/7=1_:H-XQ\*^%_
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M#+7*/\J_(^<A[V(MY_J?J /^#=S_ ()U=],\9?\ A2#_ .-4[_B'<_X)T?\
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M_P#!;+_E&C\2O^O.U_\ 2N&O*]A]7S)4[WLUK]QV*I[;".>VA_.8_2OZ'/\
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M[=5'EI<VWWW8^IC.T5W9QAJ=;"^VCNNOD8X*M*G5Y'U_,^P_^#B7_E'->_\
M8Y:7_P"A25^!7_+/FOWU_P"#B7_E'->_]CEI?_H4E?@4/N<T9'_NK]?T0LP_
MC'3>/?BM\0OBW%X;T;Q/?O>1^'-#M]%T&TAC.(K>/A45>?F8G)(ZDUZ5X%_X
M)J?MY_$GP[:^+?!?[+'BZ\TV\4FUNO[/\L./7#D,/Q%??W_!OI_P3D^'GBKP
M@W[:_P 7]!@U:Z_M"2V\'Z?=QAXK;RCM>Y93U?=PN> .>M?K<D6-NU<*HPH
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MV)(XZYK]I?\ @WV_X*->(/C+X=NOV0/C+XCGOM>\/6/VKPMJ5Y)NDN=/7"M
MS'EFB)&">2K#K@U^?W_!7G]BG2OV(_VNK[P=X.C9?"_B&U&K^&XY) S0P.Q5
MXN.R2*Z@GD@ UP7_  3Q^+&M_!7]MOX9>/M#FC21/%UI9W'G,1&8+EQ;R;N>
M@24MSQE0>U>UBJ=',,%S1UTNO(X:,IX:O9G]/>0>,T!0.0*A@82!7C.Y67(;
MUJ0M\W%?$Z]3WQU%%% !1110 4444 %%%% !1110 4444 %%%% #&Y/-9?B?
MPWX;\4:-/H_BS1[6^L)D(N+>]A5XV7W#<5ILW<5X/\8_B+KOQ;\?77P"\#WO
M]F^&])A$OQ,\:/<"*.RA(R-/AD/ GD7EVS^[0YX++5TU*]T_GV,ZJIRIM35[
MZ6[GS=<_L5:;\=/%GBK4?V*-:G\*>"]/N%M[BSU)I)M#\2ZA%*K211VY./LR
M;2K,.'<]PIKTVU_X*!>/OV>K-_!?[:7P*O/#%Q:VI2P\2>'XS<:/>%5 5=P'
M[G/3D8!. *^D/AKXF^#G]@6OA7X3^)_#LNG:9 L%K9Z+J$,B01J,!0(V./\
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MHOXM_P#!-/XPZQ\ /VKOAS;VW@_Q1=7&N^'+[P?9M-!I[L0)]JCI"3^\9?\
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M+_(H_P#!P <_\$R?&!_ZC6C?^E\-?SXG[M?T'?\ !?\ _P"49/C#'_0:T?\
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M)S=_V/O!/_@M_P#KUY']N87_ )]O\#M_L^M_,OQ/YM&\7^*P/^1EU'_P-?\
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M]33C*K"G%MI6?Y_B=_U'!O'3=KN45I=VTO?K;JCY#^,7[.GP$^&NG^#/VQO
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M$6KIN[5Y:1OIN>^W'P1\/^!_C%X%^&\?Q!\:7EG<V=_/;07WBB>6.$VL<(4
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MM'O47=))&%7+,JC)Y) ZFOM*U2G_ &:U=?#W\CY^$9?65IU_4_?ZBBBOBSZ
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M\U^CBJ1@!:\G-LRCB(^RI:KJ^YVX/"^S_>3W['PO_P '$O\ RCEO/^QRTO\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %#9VG%%!.!F@#B_C=\'-!^.OP]N?AUXEU
MO6-.M;J6*22ZT34GM9P8W#@;T/0D<@Y'X@$=/I=C%IME!I\$LSI!"L:--,TC
M, ,99F)+' Y)))[U;.#U]*:/EZ55Y<MC&-&G&LZB7O-)7\EL24>^* <C-%2;
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1@=,444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
&4444 ?_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>6
<FILENAME>fgen-20230721.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- DFIN New ActiveDisclosure (SM) XBRL Schema Document - http://www.dfinsolutions.com/ -->
<!-- Creation Date :2023-07-25T08:28:56.3706+00:00 -->
<!-- Copyright (c) 2023 Donnelly Financial Solutions, Inc. All Rights Reserved. -->
<xsd:schema targetNamespace="http://www.fibrogen.com/20230721" attributeFormDefault="unqualified" elementFormDefault="qualified" xmlns:enum2="http://xbrl.org/2020/extensible-enumerations-2.0" xmlns:fgen="http://www.fibrogen.com/20230721" xmlns:xsd="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:us-gaap="http://fasb.org/us-gaap/2023" xmlns:dei="http://xbrl.sec.gov/dei/2023" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xlink="http://www.w3.org/1999/xlink">
  <xsd:import schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" namespace="http://www.xbrl.org/2003/instance"/>
  <xsd:import schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" namespace="http://www.xbrl.org/2003/linkbase"/>
  <xsd:import schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" namespace="http://xbrl.org/2005/xbrldt"/>
  <xsd:import schemaLocation="https://xbrl.sec.gov/dei/2023/dei-2023.xsd" namespace="http://xbrl.sec.gov/dei/2023"/>
  <xsd:import schemaLocation="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd" namespace="http://fasb.org/us-gaap/2023"/>
  <xsd:annotation>
    <xsd:appinfo>
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="fgen-20230721_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:title="Labels link" xlink:type="simple"/>
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="fgen-20230721_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:title="Presentation link" xlink:type="simple"/>
      <link:roleType roleURI="http://www.fibrogen.com/20230721/taxonomy/role/DocumentDocumentAndEntityInformation" id="Role_DocumentDocumentAndEntityInformation">
        <link:definition>100000 - Document - Document And Entity Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xsd:appinfo>
  </xsd:annotation>
</xsd:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>7
<FILENAME>fgen-20230721_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- DFIN New ActiveDisclosure (SM) XBRL Linkbase Document - http://www.dfinsolutions.com/ -->
<!-- Creation Date :2023-07-25T08:28:56.3558+00:00 -->
<!-- Copyright (c) 2023 Donnelly Financial Solutions, Inc. All Rights Reserved. -->
<link:linkbase xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
  <link:roleRef roleURI="http://www.fibrogen.com/20230721/taxonomy/role/DocumentDocumentAndEntityInformation" xlink:href="fgen-20230721.xsd#Role_DocumentDocumentAndEntityInformation" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.fibrogen.com/20230721/taxonomy/role/DocumentDocumentAndEntityInformation" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentType" xlink:label="dei_DocumentType"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityInformationFormerLegalOrRegisteredName" xlink:label="dei_EntityInformationFormerLegalOrRegisteredName"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="dei_PreCommencementIssuerTenderOffer"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementTenderOffer" xlink:label="dei_PreCommencementTenderOffer"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SolicitingMaterial" xlink:label="dei_SolicitingMaterial"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_WrittenCommunications" xlink:label="dei_WrittenCommunications"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_AmendmentFlag" order="10010.0" priority="2" use="optional"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_CityAreaCode" order="10130.0" priority="2" use="optional"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentPeriodEndDate" order="10020.0" priority="2" use="optional"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentType" order="10000.0" priority="2" use="optional"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressAddressLine1" order="10090.0" priority="2" use="optional"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressCityOrTown" order="10100.0" priority="2" use="optional"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressPostalZipCode" order="10120.0" priority="2" use="optional"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressStateOrProvince" order="10110.0" priority="2" use="optional"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityCentralIndexKey" order="10040.0" priority="2" use="optional"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityEmergingGrowthCompany" order="10050.0" priority="2" use="optional"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityFileNumber" order="10060.0" priority="2" use="optional"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityIncorporationStateCountryCode" order="10070.0" priority="2" use="optional"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityInformationFormerLegalOrRegisteredName" order="10150.0" priority="2" use="optional"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityRegistrantName" order="10030.0" priority="2" use="optional"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityTaxIdentificationNumber" order="10080.0" priority="2" use="optional"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_LocalPhoneNumber" order="10140.0" priority="2" use="optional"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_PreCommencementIssuerTenderOffer" order="10190.0" priority="2" use="optional"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_PreCommencementTenderOffer" order="10180.0" priority="2" use="optional"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_Security12bTitle" order="10210.0" priority="2" use="optional"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_SecurityExchangeName" order="10340.0" priority="2" use="optional"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_SolicitingMaterial" order="10170.0" priority="2" use="optional"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_TradingSymbol" order="10220.0" priority="2" use="optional"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_WrittenCommunications" order="10160.0" priority="2" use="optional"/>
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>8
<FILENAME>fgen-20230721_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- DFIN New ActiveDisclosure (SM) XBRL Linkbase Document - http://www.dfinsolutions.com/ -->
<!-- Creation Date :2023-07-25T08:28:56.3568+00:00 -->
<!-- Copyright (c) 2023 Donnelly Financial Solutions, Inc. All Rights Reserved. -->
<link:linkbase xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:title="labelLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentType" xlink:label="dei_DocumentType"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityInformationFormerLegalOrRegisteredName" xlink:label="dei_EntityInformationFormerLegalOrRegisteredName"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="dei_PreCommencementIssuerTenderOffer"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementTenderOffer" xlink:label="dei_PreCommencementTenderOffer"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SolicitingMaterial" xlink:label="dei_SolicitingMaterial"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_WrittenCommunications" xlink:label="dei_WrittenCommunications"/>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_CoverAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cover [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_AmendmentFlag_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Amendment Flag</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_CityAreaCode_lbl" xlink:role="http://www.xbrl.org/2003/role/label">City Area Code</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentPeriodEndDate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Period End Date</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentType_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Type</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressAddressLine1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Address Line One</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressCityOrTown_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, City or Town</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressPostalZipCode_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Postal Zip Code</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressStateOrProvince_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, State or Province</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityCentralIndexKey_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Central Index Key</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Emerging Growth Company</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityFileNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Securities Act File Number</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Incorporation, State or Country Code</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityInformationFormerLegalOrRegisteredName_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Information, Former Legal or Registered Name</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityRegistrantName_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Registrant Name</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Tax Identification Number</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_LocalPhoneNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Local Phone Number</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Pre-commencement Issuer Tender Offer</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_PreCommencementTenderOffer_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Pre-commencement Tender Offer</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_Security12bTitle_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Title of 12(b) Security</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_SecurityExchangeName_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Security Exchange Name</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_SolicitingMaterial_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Soliciting Material</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_TradingSymbol_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Trading Symbol</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_WrittenCommunications_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Written Communications</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityInformationFormerLegalOrRegisteredName" xlink:to="dei_EntityInformationFormerLegalOrRegisteredName_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementIssuerTenderOffer" xlink:to="dei_PreCommencementIssuerTenderOffer_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementTenderOffer" xlink:to="dei_PreCommencementTenderOffer_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SolicitingMaterial" xlink:to="dei_SolicitingMaterial_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_WrittenCommunications" xlink:to="dei_WrittenCommunications_lbl"/>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>9
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm139682599924096">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Document And Entity Information<br></strong></div></th>
<th class="th"><div>Jul. 21, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Jul. 21,  2023<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">FIBROGEN, INC.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0000921299<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Securities Act File Number</a></td>
<td class="text">001-36740<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">77-0357827<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">409 Illinois Street<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">San Francisco<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">CA<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">94158<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">415<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">978-1200 <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityInformationFormerLegalOrRegisteredName', window );">Entity Information, Former Legal or Registered Name</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre-commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre-commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, $0.01 par value<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">FGEN<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInformationFormerLegalOrRegisteredName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Former Legal or Registered Name of an entity</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInformationFormerLegalOrRegisteredName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Section 14a<br> -Number 240<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>10
<FILENAME>fgen-20230721_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2023"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="fgen-20230721.xsd" xlink:type="simple"/>
    <context id="C_e77ac38f-730b-418a-9522-10e9d9662f00">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921299</identifier>
        </entity>
        <period>
            <startDate>2023-07-21</startDate>
            <endDate>2023-07-21</endDate>
        </period>
    </context>
    <dei:EntityCentralIndexKey
      contextRef="C_e77ac38f-730b-418a-9522-10e9d9662f00"
      id="F_28525c66-114b-4455-8cdf-d39c53a4ae78">0000921299</dei:EntityCentralIndexKey>
    <dei:AmendmentFlag
      contextRef="C_e77ac38f-730b-418a-9522-10e9d9662f00"
      id="F_1c583dd6-6009-405c-ab35-0f3b37fcbbeb">false</dei:AmendmentFlag>
    <dei:DocumentType
      contextRef="C_e77ac38f-730b-418a-9522-10e9d9662f00"
      id="F_abfea4ff-d22c-4a80-a9cf-1a47aff7dc79">8-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate
      contextRef="C_e77ac38f-730b-418a-9522-10e9d9662f00"
      id="F_f77a6d00-8aba-476d-b247-8e45d90b5eed">2023-07-21</dei:DocumentPeriodEndDate>
    <dei:EntityRegistrantName
      contextRef="C_e77ac38f-730b-418a-9522-10e9d9662f00"
      id="F_babd7872-b8c5-42e3-ba49-27c54ea88821">FIBROGEN, INC.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode
      contextRef="C_e77ac38f-730b-418a-9522-10e9d9662f00"
      id="F_9bdf4ac8-6726-40de-8fd0-46c78d1f9f09">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber
      contextRef="C_e77ac38f-730b-418a-9522-10e9d9662f00"
      id="F_06523b41-fb4e-4388-a66c-61a8b0656083">001-36740</dei:EntityFileNumber>
    <dei:EntityTaxIdentificationNumber
      contextRef="C_e77ac38f-730b-418a-9522-10e9d9662f00"
      id="F_72499b12-0b3c-4635-b3d6-db8c85b75a99">77-0357827</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1
      contextRef="C_e77ac38f-730b-418a-9522-10e9d9662f00"
      id="F_dc16f38a-e4ed-4b94-9f58-96be233595c0">409 Illinois Street</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown
      contextRef="C_e77ac38f-730b-418a-9522-10e9d9662f00"
      id="F_818421e8-4e43-49ac-b38f-40bc25e274b7">San Francisco</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="C_e77ac38f-730b-418a-9522-10e9d9662f00"
      id="F_0c4cd83b-260a-48af-a3ac-e2425b9518fb">CA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode
      contextRef="C_e77ac38f-730b-418a-9522-10e9d9662f00"
      id="F_96beb298-3e34-4b58-8691-b36eebae1e13">94158</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="C_e77ac38f-730b-418a-9522-10e9d9662f00"
      id="F_2db9c82d-1140-43d7-b9c2-9e9a56b24fa0">415</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="C_e77ac38f-730b-418a-9522-10e9d9662f00"
      id="F_93c532ed-98e4-4a54-9cf6-bf9f6d41406f">978-1200 </dei:LocalPhoneNumber>
    <dei:EntityInformationFormerLegalOrRegisteredName
      contextRef="C_e77ac38f-730b-418a-9522-10e9d9662f00"
      id="F_16532756-416c-4bb5-995e-205b60270b17"/>
    <dei:WrittenCommunications
      contextRef="C_e77ac38f-730b-418a-9522-10e9d9662f00"
      id="F_b7a198e0-6ddf-4758-af37-f9cd9d5bdb59">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial
      contextRef="C_e77ac38f-730b-418a-9522-10e9d9662f00"
      id="F_79df25e5-55d0-48a5-9152-59cef5055e4c">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer
      contextRef="C_e77ac38f-730b-418a-9522-10e9d9662f00"
      id="F_f0a16506-03f6-471a-ab6f-7ea6b6215221">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer
      contextRef="C_e77ac38f-730b-418a-9522-10e9d9662f00"
      id="F_bae60d11-362a-4cfd-9abe-29971de18455">false</dei:PreCommencementIssuerTenderOffer>
    <dei:Security12bTitle
      contextRef="C_e77ac38f-730b-418a-9522-10e9d9662f00"
      id="F_77947213-815a-414f-9ed9-948b4503bb96">Common Stock, $0.01 par value</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="C_e77ac38f-730b-418a-9522-10e9d9662f00"
      id="F_bc1453c0-2c15-4b23-89f1-52c000d8dee8">FGEN</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="C_e77ac38f-730b-418a-9522-10e9d9662f00"
      id="F_1fe65379-76d4-4f29-99ab-d1e4d714e185">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityEmergingGrowthCompany
      contextRef="C_e77ac38f-730b-418a-9522-10e9d9662f00"
      id="F_0e7803b9-98e5-4186-ab5f-6543f1592e16">false</dei:EntityEmergingGrowthCompany>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>11
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M-RNI8FYPJ-9-G2K@86X41TW?=:^:,1>),QKD]^9J-)"9B40"<\5T%L=<O=]
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MV7;[;!;A72DT;HC"8DFAEJG?HY/W1]2)'>%6/\MM=>6DY18\85-,38'0@:0
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MXWE^N0&.468GX/<K*<UA8,_HQ4\LHW\ 4$L#!!0    (  Y$^5:?H!OPL0(
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M%_\;SO$1PNZ_/[&\UDX:?^:+X3]>?P%02P$"% ,4    "  .1/E6!T%-8H$
M  "Q    $               @ $     9&]C4')O<',O87!P+GAM;%!+ 0(4
M Q0    (  Y$^59DU*"X[@   "L"   1              "  :\   !D;V-0
M<F]P<R]C;W)E+GAM;%!+ 0(4 Q0    (  Y$^5:97)PC$ 8  )PG   3
M          "  <P!  !X;"]T:&5M92]T:&5M93$N>&UL4$L! A0#%     @
M#D3Y5D_KD.)]!   ;A$  !@              ("!#0@  'AL+W=O<FMS:&5E
M=',O<VAE970Q+GAM;%!+ 0(4 Q0    (  Y$^5:?H!OPL0(  .(,   -
M          "  < ,  !X;"]S='EL97,N>&UL4$L! A0#%     @ #D3Y5I>*
MNQS     $P(   L              ( !G \  %]R96QS+RYR96QS4$L! A0#
M%     @ #D3Y5CJJHN=  0  / (   \              ( !A1   'AL+W=O
M<FMB;V]K+GAM;%!+ 0(4 Q0    (  Y$^58D'INBK0   /@!   :
M      "  ?(1  !X;"]?<F5L<R]W;W)K8F]O:RYX;6PN<F5L<U!+ 0(4 Q0
M   (  Y$^59ED'F2&0$  ,\#   3              "  =<2  !;0V]N=&5N
B=%]4>7!E<UTN>&UL4$L%!@     )  D /@(  "$4      $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>14
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.23.2</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>1</ContextCount>
  <ElementCount>23</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>0</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>0</UnitCount>
  <MyReports>
    <Report instance="fgen-20230721.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>100000 - Document - Document And Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.fibrogen.com/20230721/taxonomy/role/DocumentDocumentAndEntityInformation</Role>
      <ShortName>Document And Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="8-K" original="fgen-20230721.htm">fgen-20230721.htm</File>
    <File>fgen-20230721.xsd</File>
    <File>fgen-20230721_lab.xml</File>
    <File>fgen-20230721_pre.xml</File>
    <File>fgen-ex10_1.htm</File>
    <File>fgen-ex10_2.htm</File>
    <File>fgen-ex99_1.htm</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="23">http://xbrl.sec.gov/dei/2023</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>16
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "fgen-20230721.htm": {
   "axisCustom": 0,
   "axisStandard": 0,
   "baseTaxonomies": {
    "http://xbrl.sec.gov/dei/2023": 23
   },
   "contextCount": 1,
   "dts": {
    "inline": {
     "local": [
      "fgen-20230721.htm"
     ]
    },
    "labelLink": {
     "local": [
      "fgen-20230721_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "fgen-20230721_pre.xml"
     ]
    },
    "schema": {
     "local": [
      "fgen-20230721.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd",
      "https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd",
      "https://xbrl.fasb.org/srt/2023/elts/srt-roles-2023.xsd",
      "https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd",
      "https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd",
      "https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd",
      "https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd",
      "https://xbrl.sec.gov/country/2023/country-2023.xsd",
      "https://xbrl.sec.gov/dei/2023/dei-2023.xsd"
     ]
    }
   },
   "elementCount": 24,
   "entityCount": 1,
   "hidden": {
    "http://xbrl.sec.gov/dei/2023": 2,
    "total": 2
   },
   "keyCustom": 0,
   "keyStandard": 23,
   "memberCustom": 0,
   "memberStandard": 0,
   "nsprefix": "fgen",
   "nsuri": "http://www.fibrogen.com/20230721",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "body",
       "html"
      ],
      "baseRef": "fgen-20230721.htm",
      "contextRef": "C_e77ac38f-730b-418a-9522-10e9d9662f00",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "100000 - Document - Document And Entity Information",
     "menuCat": "Cover",
     "order": "1",
     "role": "http://www.fibrogen.com/20230721/taxonomy/role/DocumentDocumentAndEntityInformation",
     "shortName": "Document And Entity Information",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "body",
       "html"
      ],
      "baseRef": "fgen-20230721.htm",
      "contextRef": "C_e77ac38f-730b-418a-9522-10e9d9662f00",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 0,
   "tag": {
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://www.fibrogen.com/20230721/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://www.fibrogen.com/20230721/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "xbrltype": "stringItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://www.fibrogen.com/20230721/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://www.fibrogen.com/20230721/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://www.fibrogen.com/20230721/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://www.fibrogen.com/20230721/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://www.fibrogen.com/20230721/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://www.fibrogen.com/20230721/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://www.fibrogen.com/20230721/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://www.fibrogen.com/20230721/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Securities Act File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://www.fibrogen.com/20230721/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://www.fibrogen.com/20230721/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityInformationFormerLegalOrRegisteredName": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Former Legal or Registered Name of an entity",
        "label": "Entity Information, Former Legal or Registered Name"
       }
      }
     },
     "localname": "EntityInformationFormerLegalOrRegisteredName",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://www.fibrogen.com/20230721/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://www.fibrogen.com/20230721/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://www.fibrogen.com/20230721/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://www.fibrogen.com/20230721/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "auth_ref": [
      "r3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.",
        "label": "Pre-commencement Issuer Tender Offer"
       }
      }
     },
     "localname": "PreCommencementIssuerTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://www.fibrogen.com/20230721/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_PreCommencementTenderOffer": {
     "auth_ref": [
      "r4"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.",
        "label": "Pre-commencement Tender Offer"
       }
      }
     },
     "localname": "PreCommencementTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://www.fibrogen.com/20230721/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://www.fibrogen.com/20230721/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://www.fibrogen.com/20230721/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_SolicitingMaterial": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.",
        "label": "Soliciting Material"
       }
      }
     },
     "localname": "SolicitingMaterial",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://www.fibrogen.com/20230721/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://www.fibrogen.com/20230721/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "dei_WrittenCommunications": {
     "auth_ref": [
      "r6"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.",
        "label": "Written Communications"
       }
      }
     },
     "localname": "WrittenCommunications",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://www.fibrogen.com/20230721/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    }
   },
   "unitCount": 0
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r1": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r2": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r3": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13e",
   "Subsection": "4c",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r4": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14d",
   "Subsection": "2b",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r5": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14a",
   "Subsection": "12",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r6": {
   "Name": "Securities Act",
   "Number": "230",
   "Publisher": "SEC",
   "Section": "425",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  }
 },
 "version": "2.2"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>17
<FILENAME>0000950170-23-034234-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0000950170-23-034234-xbrl.zip
M4$L#!!0    (  Y$^58#!30RE2$  -=H 0 1    9F=E;BTR,#(S,#<R,2YH
M=&WM/6EWV\B1W_,K>I5DGO26H  0( '*=IXL2PXSMN1(FIV\_9+7 !IDQR#
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MST/I=Q;0X8^MT*=!PI86=S@/TICY+ 99S9(/[Y!K^XE@$IB(""[N(Z^]WTL
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M!X/!<:AD#FL.&P)%B+@U!5$;(^SE3@"@FFVK0BVAC)Z /HE2>6W_8:@)D!3
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M67O#6J-O57M>HP<'MC5TCG5C:2Z9\S]02P,$%     @ #D3Y5GH&,6_<!0
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M;CGYU9R$GP@[]BC>?8!BM\>O_-N.:SC:0+(_?[AN1ZH.=O"$84N)EA(M)?:
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M1H9Y%@T;,!? D$% -051Q!:?8*^U]X56!?KI;I",0)J1[JCDD6\""O;?"^$
M<Q)M^9E2* M,BY,XE/Y4&TGY&[7AHX0<]S.5B%I)HP1'.PX-(C!\MN+!UB3V
MOXBT.A2/G$;?CU50](W"$:4>;%-T@3Z7T6U,,LP-1%8DF9T?,JW2>'O>V3-'
MA9):=O>W]_?W?SY;"&C/$A[&<UC$#*WL:SZE==]X?\KL?YO-"OQ <>C"VIL)
M?[X)KP'--]/^_-->34LXU^D(S=3_ "%__5^Y%0,618/C76%G9&'GXTG3]1=I
M/NI0S2\_&2-E^S+A0['5QVR,+4+)G?+P#ARJ!62->/E96ZPCM82JYM4,1L5
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M1N[[\T\K(YWGV;=#2M,L,@LI[=Y2KNE2 0-V :<+Q&PDN;5F*S4\X9GS,73
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MS"R?"H_P0<F4O;8 (,"H8#\1YP%JG&C/Z0GP)A"),DCE>NQ7RL00HOYA@#O
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M&(JBTJ;;%J/"#C.N*%T>0B8 N+C&*"%J4A*RN)CZ?WW^[MEWD)/*>I1?DWI
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M,C R,S W,C$N:'1M4$L! A0#%     @ #D3Y5I%B3@X. P  I D  !$
M         ( !Q"$  &9G96XM,C R,S W,C$N>'-D4$L! A0#%     @ #D3Y
M5GH&,6_<!0  H30  !4              ( ! 24  &9G96XM,C R,S W,C%?
M;&%B+GAM;%!+ 0(4 Q0    (  Y$^5:S7(IJJ 0  *LF   5
M  "  1 K  !F9V5N+3(P,C,P-S(Q7W!R92YX;6Q02P$"% ,4    "  .1/E6
M%P8H+WH,  #E@@  #P              @ 'K+P  9F=E;BUE>#$P7S$N:'1M
M4$L! A0#%     @ #D3Y5L^]T5L5(P  1&0!  \              ( !DCP
M &9G96XM97@Q,%\R+FAT;5!+ 0(4 Q0    (  Y$^5:'.JL_J0T  -I6   /
M              "  =1?  !F9V5N+65X.3E?,2YH=&U02P4&      < !P"[
) 0  JFT

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
